Sargramostim in patients with Crohn's disease: Results of a phase 1-2 study

Journal of Gastroenterology

Volumn 44, Issue 6, 2009, Pages 535-543

  Takazoe, Masakazu ^a   Matsui, Toshiyuki ^b   Motoya, Satoshi ^c   Matsumoto, Takayuki ^d   Hibi, Toshifumi ^e   Watanabe, Mamoru ^f  

^a Social Insurance Central General Hospital   (Japan)

^b Fukuoka University Chikushi Hospital   (Japan)

^c Sapporo Kosei General Hospital   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Crohn's disease; Crohn's disease activity index (CDAI); Inflammatory bowel disease; Sargramostim

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIULCER AGENT; MESALAZINE; PLACEBO; PROBIOTIC AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SALICYLIC ACID DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ENTERIC FEEDING; FEMALE; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; INJECTION SITE REACTION; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; HYPODERMOCLYSIS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED;

EID: 67449101468     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0029-7     Document Type: Article

References (15)

1. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: A systematic review. Aliment Pharmacol Ther. 2002;16:51-60.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-29.
3. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilberg MJ, Sargramostim in Crohn's Disease Study Group. Sargramostim for active Crohn's disease. N Engl J Med. 2005;352:2193-201.
4. Korzenik JR, Dieckgraefe BK. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci. 2000;45:1121-9.
5. Wilks JN, Viney JL. GM-CSF treatment for Crohn's disease: A stimulating new therapy? Curr Opin Investig Drugs. 2002;3:1291-6.
6. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1998;92:4491-508.
7. Fukuzawa H, Sawada M, Kayahara T, Morita-Fujisawa Y, Suzuki K, Seno H, et al. Identification of GM-CSF in Paneth cells using single-cell RT-PCR. Biochem Biophys Res Commun. 2003;312:897-902.
8. LEUKINE® (sargramostim). Bayer HealthCare Pharmaceuticals, Seattle, WA. Revised April 2008. http://www.leukine.com/hcp/index.jsp. Accessed 28 Sept 2008.
9. Neumunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogenic bone marrow transplantation. Bone Marrow Transplant. 1995;15:949-54.
10. Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, et al. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol. 1996;14:2976-83.
11. Meropol NJ, Rustum YM, Creaven PJ, Blumenson LE, Frank C. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: A potential role for growth factor as mucosal protectant. Cancer Invest. 1999;17:1-9.
12. Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther. 2005;21:391-400.
13. Dieckgraefe BR, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet. 2002;360:1478-80.
14. Valentine JF, Fedorak RN, Fredlund P, Feagan BG, for the Sargramostim CD Study Group. Sargramostim induces steroid-free remission in corticosteroid-dependent Crohn's disease: Results of NOVEL 2, a phase II multicenter study. Presented at Digestive Diseases Week, Washington DC, 19-24 May 2007.
15. Bayer HealthCare. Phase 3 randomized, double-blind, placebo-controlled induction study of sargramostim (Leukine®) in subjects with active Crohn's disease. http://www.clinicalstudyresults.org/drugdetails/ ?inn_name_id=474&sort=c.company_name&page=1&drug_id=2435. Accessed 28 Sept 2008.